NCT04333368View on ClinicalTrials.gov

Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions
Severe Acute Respiratory Syndrome Coronavirus 2Severe Acute Respiratory Distress Syndrome
Interventions
BIOLOGICAL

Umbilical cord Wharton's jelly-derived human

Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 60 minutes, using tubing with a 200-μm filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.

OTHER

NaCl 0.9%

NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5

Trial Locations (2)

75013

Hôpital Pitié-Salpêtrière - APHP, Paris

75015

Hôpital Européen Georges Pompidou - APHP, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04333368 - Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS | Biotech Hunter | Biotech Hunter